Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 2005.0
(-0.25%)
KRW 2005.0
(-0.25%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 40.37 Billion KRW | 46.37% |
| 2022 | 27.58 Billion KRW | 1181.48% |
| 2021 | 2.15 Billion KRW | -45.48% |
| 2020 | 3.94 Billion KRW | -35.5% |
| 2019 | 6.12 Billion KRW | -24.66% |
| 2018 | 8.12 Billion KRW | -21.05% |
| 2017 | 10.29 Billion KRW | -17.39% |
| 2016 | 12.45 Billion KRW | -9.57% |
| 2015 | 13.77 Billion KRW | 140.43% |
| 2014 | 5.73 Billion KRW | 85.07% |
| 2013 | 3.09 Billion KRW | -67.83% |
| 2012 | 9.62 Billion KRW | 6.51% |
| 2011 | 9.03 Billion KRW | 486.93% |
| 2010 | 1.53 Billion KRW | -24.02% |
| 2009 | 2.02 Billion KRW | -18.1% |
| 2008 | 2.47 Billion KRW | -9.46% |
| 2007 | 2.73 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 29.79 Billion KRW | -0.91% |
| 2024 Q1 | 30.06 Billion KRW | -25.54% |
| 2023 Q1 | 41.07 Billion KRW | 48.91% |
| 2023 Q3 | 38.92 Billion KRW | -2.04% |
| 2023 Q2 | 39.72 Billion KRW | -3.28% |
| 2023 FY | 40.37 Billion KRW | 46.37% |
| 2023 Q4 | 40.37 Billion KRW | 3.75% |
| 2022 Q1 | 1.36 Billion KRW | -36.41% |
| 2022 Q2 | 10.67 Billion KRW | 680.05% |
| 2022 Q3 | 8.86 Billion KRW | -16.96% |
| 2022 Q4 | 27.58 Billion KRW | 211.14% |
| 2022 FY | 27.58 Billion KRW | 1181.48% |
| 2021 FY | 2.15 Billion KRW | -45.48% |
| 2021 Q1 | 3.66 Billion KRW | -7.24% |
| 2021 Q2 | 3.7 Billion KRW | 1.28% |
| 2021 Q3 | 2.9 Billion KRW | -21.58% |
| 2021 Q4 | 2.15 Billion KRW | -26.0% |
| 2020 Q3 | 4.51 Billion KRW | -10.5% |
| 2020 Q2 | 5.03 Billion KRW | -9.58% |
| 2020 Q1 | 5.57 Billion KRW | -8.96% |
| 2020 FY | 3.94 Billion KRW | -35.5% |
| 2020 Q4 | 3.94 Billion KRW | -12.47% |
| 2019 Q2 | 7.23 Billion KRW | -7.55% |
| 2019 Q3 | 6.66 Billion KRW | -7.99% |
| 2019 Q4 | 6.12 Billion KRW | -8.1% |
| 2019 FY | 6.12 Billion KRW | -24.66% |
| 2019 Q1 | 7.83 Billion KRW | -3.62% |
| 2018 Q2 | 9.2 Billion KRW | -5.55% |
| 2018 Q4 | 8.12 Billion KRW | -6.25% |
| 2018 FY | 8.12 Billion KRW | -21.05% |
| 2018 Q1 | 9.75 Billion KRW | -5.26% |
| 2018 Q3 | 8.66 Billion KRW | -5.88% |
| 2017 Q3 | 10.83 Billion KRW | -4.76% |
| 2017 Q4 | 10.29 Billion KRW | -5.0% |
| 2017 FY | 10.29 Billion KRW | -17.39% |
| 2017 Q1 | 11.91 Billion KRW | -4.35% |
| 2017 Q2 | 11.37 Billion KRW | -4.55% |
| 2016 Q4 | 12.45 Billion KRW | -4.17% |
| 2016 FY | 12.45 Billion KRW | -9.57% |
| 2016 Q3 | 13 Billion KRW | -1.77% |
| 2016 Q2 | 13.23 Billion KRW | -1.74% |
| 2016 Q1 | 13.46 Billion KRW | -2.24% |
| 2015 Q2 | 10.53 Billion KRW | 43.97% |
| 2015 Q4 | 13.77 Billion KRW | -2.06% |
| 2015 Q3 | 14.06 Billion KRW | 33.57% |
| 2015 Q1 | 7.31 Billion KRW | 27.66% |
| 2015 FY | 13.77 Billion KRW | 140.43% |
| 2014 Q1 | 2.8 Billion KRW | -9.38% |
| 2014 Q2 | 2.51 Billion KRW | -10.33% |
| 2014 FY | 5.73 Billion KRW | 85.07% |
| 2014 Q4 | 5.73 Billion KRW | 58.84% |
| 2014 Q3 | 3.6 Billion KRW | 43.38% |
| 2013 Q3 | 10.33 Billion KRW | -0.54% |
| 2013 Q4 | 3.09 Billion KRW | -70.04% |
| 2013 Q2 | 10.39 Billion KRW | -0.53% |
| 2013 FY | 3.09 Billion KRW | -67.83% |
| 2013 Q1 | 10.44 Billion KRW | 8.55% |
| 2012 FY | 9.62 Billion KRW | 6.51% |
| 2012 Q4 | 9.62 Billion KRW | 5.21% |
| 2012 Q3 | 9.14 Billion KRW | 2.66% |
| 2012 Q2 | 8.91 Billion KRW | -0.62% |
| 2012 Q1 | 8.96 Billion KRW | -0.78% |
| 2011 FY | 9.03 Billion KRW | 486.93% |
| 2011 Q2 | 1.28 Billion KRW | -8.9% |
| 2011 Q1 | 1.41 Billion KRW | -8.17% |
| 2011 Q4 | 9.03 Billion KRW | 677.53% |
| 2011 Q3 | 1.16 Billion KRW | -9.77% |
| 2010 Q1 | 1.9 Billion KRW | -6.21% |
| 2010 Q4 | 1.53 Billion KRW | -7.55% |
| 2010 Q3 | 1.66 Billion KRW | -7.02% |
| 2010 Q2 | 1.79 Billion KRW | -5.75% |
| 2010 FY | 1.53 Billion KRW | -24.02% |
| 2009 Q1 | 2.4 Billion KRW | -2.83% |
| 2009 Q4 | 2.02 Billion KRW | -5.85% |
| 2009 FY | 2.02 Billion KRW | -18.1% |
| 2009 Q2 | 2.33 Billion KRW | -2.92% |
| 2009 Q3 | 2.15 Billion KRW | -7.79% |
| 2008 Q2 | 2.61 Billion KRW | -2.61% |
| 2008 Q4 | 2.47 Billion KRW | -2.76% |
| 2008 FY | 2.47 Billion KRW | -9.46% |
| 2008 Q3 | 2.54 Billion KRW | -2.68% |
| 2008 Q1 | 2.68 Billion KRW | -1.76% |
| 2007 Q1 | 1.4 Billion KRW | 0.0% |
| 2007 Q4 | 2.73 Billion KRW | -2.5% |
| 2007 Q3 | 2.8 Billion KRW | 17.38% |
| 2007 Q2 | 2.38 Billion KRW | 70.32% |
| 2007 FY | 2.73 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -150.363% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -35.148% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 18.541% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 80.017% |
| HANDOK Inc. | 123.78 Billion KRW | 67.379% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -26.181% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -567.402% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -112.206% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -6740.112% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -220.861% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -18340.639% |
| CKD Bio Corp. | 69.43 Billion KRW | 41.845% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -172.36% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -196.024% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -284.551% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 66.63% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 75.074% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 56.776% |
| Yuhan Corporation | 60.23 Billion KRW | 32.965% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -34.593% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -196.024% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -34.593% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 50.776% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -117.994% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -8387.319% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -6853.944% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -869.074% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -2425.435% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 44.007% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -34.593% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -16.784% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -13049.972% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -34.593% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -196.024% |
| Yuhan Corporation | 60.23 Billion KRW | 32.965% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -39556.927% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -33638.592% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -268.327% |
| JW Holdings Corporation | 20.65 Billion KRW | -95.465% |
| Suheung Co., Ltd. | 74 Billion KRW | 45.441% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -806.958% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -18340.639% |
| Boryung Corporation | 151.7 Billion KRW | 73.385% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 48.58% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -567.402% |
| JW Lifescience Corporation | 168 Million KRW | -23934.409% |